My Profile

Search abstracts

Lewis Sheiner


2017
Budapest, Hungary



2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
København, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK
   Program
   Abstracts


1993
Paris, France

1992
Basel, Switzerland

Printable version

Monday June 13
09:00-10:00 Registration and coffee
   
Oral session I Free communications I chair: Lewis Sheiner
10:00-10:15 N. Baber Introduction
10:15-10:30  C. Peck, T. Ludden Pitfalls in retrospective analysis in search of concentration-effect relationships
10:30-10:45 M.O. Karlsson, S.L. Beal, L.B. Sheiner Three new residual error models for population PK/PD analyses
10:45-11:00 J.R. Wade, S.L. Beal, N.C. Sambol Interaction between structural, statistical and covariate models in population pharmacokinetic analysis
11:00-11:15 J.W. Mandema, D. Verotta, L.B. Sheiner Diagnostics for nonlinear mixed effects models
11:15-11:30 Coffee break
Oral session II Free communications II chair: Lewis Sheiner
11:30-11:45 Y. Merle, F. Mentré Comparison of Bayesian optimal designs with respect to variations of the population characteristics for a pharmacokinetic and a pharmacodynamic model
11:45-12:00 C. Efthymiopoulos, V. Cosson, A. Bye The use of NONMEM in the interspecies allometric scaling
12:00-12:15 A.V. Boddy, M. Cole, P. Bin, A.D.J. Pearson, D.R. Newell A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics
12:15-12:30 E. Chatelut, V. Brunner, C. Chevreau, A. Pujol, H. Roche, V. Paschel, G. Houin, R. Bugat, P. Canal Carboplatin population pharmacokinetics
12:30-14:00 Lunch
   
Oral session III Population approach in drug development : present state chair: Alison Thomson
14:00-14:20 A. Bye Issues and suggested solutions in drug development (Logistics/Models/Regulatory)
14:20-14:40 R. Bruno, N. Vivier, J.C. Vergniol, G. Montay, L.B. Sheiner A validation for a population pharmacokinetic model for docetaxel
14:40-15:15 A. Grieve Combining studies: opportunities and pitfalls
15:15-15:45 Tea break
   
Oral session IV Population approach in drug development : future chair: Willi Weber
15:45-16:05 J.-L Steimer, M.-E. Ebelin Implementation of pharmacometric approaches into clinical drug development? A prospective view
16:05-16:25 L.B. Sheiner The future place of modeling in drug development
16:25-16:45 C. Peck, F. Mentre, L. Aarons Discussion
       
16:45-17:00 Future of PAG(E) : Proposals: P. Girard
17:00-18:00 Poster and software session (see below)
 

Tuesday June 14
Oral session V chair: Carl Peck
09:00-09:45 J. Wakefield Tutorial : Review of methods
09:45-10:15  L. Aarons Software+ COST recommendations
10:15-10:45 S. Lettis, E. Fuseau Simulation data : status report
10:45-11:00 P. Girard Future of PAG(E) : Decision
11:00-11:30 Coffee break
11:30-14:00 Poster and software session (see below)
   
14:00 End of the meeting

 

Software demonstrations:
APIS (A. Iliadis)
MICROPHARM (S.Urien)
NONMEM PC (C.Pobel)
NONMEM VAX (V. Cosson)
NPEM (X. Barbaut)
NPML (Y. Merlé)
POPKAN (J. Wakefield)
P-PHARM (R. Gomeni)

Poster Presentations
1. M.O. Karlsson Stability of covariate models.
2. L. Claret, A. Iliadis Non-parametric density estimation applied to population studies.
3. O. Petricoul, A. Iliadis, L. Claret, C. Puozzo Information theory in drug development. Applications to a new antidepressant.
4. J. Bennett, J.C. Wakefield Covariate identification for population pharmacokinetic modelling.
5. S. Walker, J.C. Wakefield The population analysis of a dose ranging study.
6. E.M. Parker, M. Hutchison Pharmacokinetics of meropenem in pediatrics NONMEN analysis.
7. P. Burtin, E. Jacqz-Aigrin, P. Girard  Population pharmacokinetics of midazolam in neonates.
8. D. de Alwis, L. Aarons, J. Palmer The population pharmacokinetics of ondansetron from phase I studies.
9. A.C. Falcao, M.M. Fernandez De Gatta, M.F. Delgado Iribarnegaray, D. Santos Buelga, M.J. Garcia, A. Dominguez-Gil, J.M. Lanao Caffeine pharmacokinetics in a pediatric population.
10. C. Laveille, M. Malbezin, D. Guez, R. Jochemsen Pharmacokinetics of S-12024 by a prospective population approach in phase II.
11. V. Cosson, J.-M. Scherrmann, E. Fuseau Population pharmacokinetics of oral sumatriptan.
12. S.F. Marshall, H.L. Elliott, P.A. Meredith A population approach to dose versus response relationship for simvastatin in hypertensive hypercholesterolaemic patients.
13. L.F. Lacey, L. Kler Effect of covariates on steady-state trough plasma bismuth concentrations from GR122311X in duodenal ulcer patients.
14. M. Tod, C. Pobel, O. Petitjean, N. Brion, J. Garcia-Mace A population pharmacokinetic study of alminoprofen penetration into synovial fluid.
15. M. Tod, J.M. Rocchisani Optimal sampling times determination by criteria incorporating knowledge of parameter distribution in the population.
16. N. Jonsson, J.R. Wade, M.O. Karlsson Comparison of practical sampling strategies for population pharmacokinetic studies.
17. L. Evans, L. Aarons Use of the EM algorithm in population pharmacokinetic analysis.
18. M.T. Mateu, J.J. Perez-Ruixo, V.G. Casabo, N.V. Jimenez Estimation of population pharmacokinetic parameters of tobramycin in intensive care unit patients using different programs.
19. D. Breilh, C. Pobel, L. Lagagnier, P. Maire, M.C. SauX Evaluation of bayesian estimators for adaptative control of vancomycin built with two methods of population modeling
20. B. Charpiat, N. Laurent, J.M Sab, V. Breant, C. Ducerf, S. Tigaud, D. Robert, R.W. Jelliffe Cyclosporine population pharmacokinetic parameters in the early post-operative hepatic transplantation phase: preliminary results.
21. M. Jerling, Y. Merle, F. Mentre, A. Mallet Population pharmacokinetics of nortriptyline at monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 – an evaluation with the nonparametric maximum likelihood method.